People · Operator
Named in public records as an officer, director or promoter · active 2020–2022 · Pharma, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| March Therapeutics, Inc. | — | Pharma | Series B | $23.0M | $289.6M | 2020 |
| DxLab Inc. | — | Other Health Care | Seed | $4.0M | $81.5M | 2020 |
Fahim Farzadfard at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Fahim Farzadfard on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeong Seuk Kang | 2 | 4 |
| Clare Ozawa | 1 | 8 |
| Calvin Chin | 1 | 5 |
| Adam Mullinax | 1 | 3 |
| Daniel I. DeWolf | 1 | 2 |
| Habib I. Haddad | 1 | 1 |
| Adam I. Mullinax | 1 | 1 |
| Ho-Jun Suk | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.